Meet our 2026 Speakers

Amit Gulwadi is Vice President and Head of Digital and Transformation at Alexion Pharmaceuticals, where he leads efforts to modernize clinical development through data, technology, and operational innovation.

Angi Robinson is Senior Vice President, Specialty Areas at Premier Research, where she brings more than 24 years of experience leading rare disease, pediatric, and other specialty clinical development programs globally.

Clark Paramore is the Head of Global Value Evidence Strategy at Biogen and a seasoned health economics and outcomes research expert with deep expertise in value demonstration for innovative therapies such as gene and rare disease treatments.

Craig Lipset is founder of Clinical Innovation Partners and co-founder and co-chair of the Decentralized Trials & Research Alliance, with more than 20 years of leadership in clinical trial innovation, patient-centered research, and medicine development.

Deb Kientop is Senior Vice President, Strategic Solutions & Patient Centricity at Ergomed, bringing more than 27 years of experience across clinical research, strategic trial planning, and patient-centered drug development.

Dr. Dashiell-Aje is the Executive Director and Head of Patient-Centered Outcomes Science at BioMarin Pharmaceutical, leading efforts to incorporate patient perspectives into clinical outcome assessments.

Elizabeth Duke, MD, is Senior Vice President, Drug and Biological Therapies at Canal Row Advisors, a pediatric neuro-oncologist and former clinical reviewer in oncology who brings deep prior experience from FDA review of pediatric and rare cancer therapies.

Dr. Peay is a Senior Director at Faegre Drinker Consulting, specializing in patient-focused drug development, patient engagement, and bioethics research.

Dr. Berry is an Associate Neurologist at Massachusetts General Hospital, Associate Professor of Neurology at Harvard Medical School, and clinical researcher focused on ALS biomarkers and therapeutic development.

Julia Vitarello is founder of Mila’s Miracle Foundation and a leading Batten disease advocate whose work helped catalyze the first individualized antisense therapy for an ultra-rare genetic disease.

Lauren Morgenroth is the CEO and co-founder of TRiNDS, a CRO specializing in neuromuscular and rare disease clinical trials, with deep expertise in multicenter trial operations and patient-focused research.

Marc O'Connor is a principal owner and Chief Business Officer for Curant Health, and a nationally recognized thought leader on health care delivery, collaboration, and alignment.

Dr. Binks is the Chief Medical Officer at Capricor Therapeutics, bringing over 25 years of experience in global clinical development and translational research, with a focus on immunology and rare diseases.

Rachel Smith is Vice President and Global Head of Rare Disease at Parexel, providing expertise on effective, expedited, and robust clinical development strategies for rare therapies to accelerate these much-needed options to rare patients as safely as possible.

Dr. Pryluk is CEO and co-founder of PhaseV, a health-tech company developing causal machine learning–based platforms for adaptive clinical trial design and execution.